Lantern Pharma (LTRN) Accounts Payables (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Accounts Payables came in at $3.7 million in Q1 2026, down 9.86% YoY from $4.1 million in Q1 2025, and down 15.93% on a QoQ basis from $4.4 million in Q4 2025.
Lantern Pharma (LTRN) Accounts Payables (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Accounts Payables data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Accounts Payables fell 9.86% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (down 9.86% YoY) and the FY2025 annual result came in at $4.4 million, up 6.83% from the prior year.
- Accounts Payables eased to $3.7 million in Q1 2026, from $4.4 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $5.2 million in Q2 2022 to a low of $2.1 million in Q3 2023.
- A 5-year average of $3.6 million and a median of $3.7 million in 2026 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 2590.0% — and 2023, when it slumped 44.86%.
- Tracing LTRN's Accounts Payables over 5 years: stood at $2.7 million in 2022, then declined by 8.75% to $2.5 million in 2023, then soared by 65.27% to $4.1 million in 2024, then climbed by 6.83% to $4.4 million in 2025, then fell by 15.93% to $3.7 million in 2026.
- The last three Accounts Payables figures came in at $3.7 million (Q1 2026), $4.4 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.72 Mn |
| Dec 31, 2025 | 4.42 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.12 Mn |
| Dec 31, 2024 | 4.14 Mn |
| Sep 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 4.44 Mn |
| Mar 31, 2024 | 3.78 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 2.09 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 3.05 Mn |
| Jun 30, 2022 | 5.17 Mn |
| Mar 31, 2022 | 2.92 Mn |
| Dec 31, 2021 | 2.17 Mn |
| Sep 30, 2021 | 1.64 Mn |
| Jun 30, 2021 | 1.09 Mn |